PharmaEssentia
PharmaEssentia Corporation is a Taiwan-based biopharmaceutical company focused on the development, manufacturing, and commercialization of biologic therapies for hematology and oncology indications. The company utilizes its proprietary pegylation technology platform to produce long-acting proteins, with its lead product targeted at myeloproliferative neoplasms such as polycythemia vera. Primary revenues are generated from global product sales of prescription biologics, licensing agreements, and clinical research partnerships. PharmaEssentia serves hospitals, specialty clinics, hematology specialists, and cancer treatment centers across the United States, Europe, Taiwan, and other Asian markets. The enterprise holds an established international market position as an innovative commercial-stage biopharmaceutical manufacturer. PharmaEssentia Corporation is headquartered in Taipei, Taiwan, and its common shares are listed on the Taipei Exchange.
17 of the funds FundTelligence covers report a position in PharmaEssentia.
- Legal name
- PharmaEssentia Corp
- Sector
- Health Care
- Country
- Taiwan
- Funds holding it
- 17
Funds holding PharmaEssentia
- Handelsbanken Asia SMB — Handelsbanken · 1.53 % (full portfolio disclosed, August 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.92 % (full portfolio disclosed, September 2026)
- Handelsbanken Asia Tema — Handelsbanken · 0.21 % (full portfolio disclosed, August 2026)
- SEB Emerging Markets Exposure — SEB · 0.15 % (full portfolio disclosed, June 2026)
- Lannebo Emerging Markets — Lannebo · 0.14 % (full portfolio disclosed, June 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.12 % (full portfolio disclosed, July 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.11 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 17 funds holding it.